|Reference : Oral glucose tolerance tests in schizophrenic patients treated with antipsychotics|
|Scientific congresses and symposiums : Paper published in a journal|
|Social & behavioral sciences, psychology : Neurosciences & behavior|
Human health sciences : Neurology
|Oral glucose tolerance tests in schizophrenic patients treated with antipsychotics|
|De Hert, Marc [> > > >]|
|Van Eyck, Dominique [> > > >]|
|Hermans, Gilberte [Centre Hospitalier Universitaire de Liège - CHU > > Anatomie pathologique >]|
|Peuskens, Hendrik [> > > >]|
|Wampers, Martien [> > > >]|
|de Patoul, A. [> > > >]|
|Hanssens, L. [> > > >]|
|Scheen, André [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale]|
|Peuskens, Jozef [> > > >]|
|International Journal of Neuropsychopharmacology|
|Cambridge Univ Press|
|[en] Schizophrenia ; Diabetes ; Metabolic syndrome; ; Antipsychotics|
|[en] Objective. –A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also
identifies the need of long-term prospective studies.
Method. – A large scale prospective study on metabolic risks of antipsychotic medication is currently ongoing. At baseline, patients get a
full laboratory screening, ECG and an oral glucose tolerance test (OGTT). Baseline data on 100 non-diabetic patients at study inclusion and
stable on medication for at least 6 months are presented.
Results. – Glucose abnormalities are found in 22% of patients at baseline.A monitoring protocol based only on fasting glucose would not
have detected 63.6% of these patients with classifiable glucose abnormalities in our sample. Fasting insulin and measures for insulin resistance
have a high predictive value for abnormalities late in the OGTT.
Conclusion. – Already at baseline, metabolic problems are frequently present in patients with schizophrenia treated with antipsychotics.
Adding assessment of fasting insulin in a monitoring protocol improves detection of glucose abnormalities late in an OGTT.
|Researchers ; Professionals ; Students|
|© 2005 Elsevier SAS. All rights reserved.|
|File(s) associated to this reference|
All documents in ORBi are protected by a user license.